Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety

PARP inhibitors have been approved by the FDA for use in the treatment of patients with ovarian, breast, pancreatic, and prostate cancers. PARP inhibitors show diverse suppressive effects on PARP family members and PARP-DNA trapping potency. These properties are associated with distinct safety/effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Myongjae, Je, In-Gyu, Kim, Jeong Eun, Yoo, Yeongran, Lim, Jong-Ha, Jang, Eunhye, Lee, Yoonsuk, Song, Dong Keun, Moon, An-Na, Kim, Jeong-Ah, Jeong, Jinah, Park, Joon-Tae, Lee, Jung Woo, Yang, Ji-Hoon, Hong, Chang-Hee, Park, Sun-Young, Park, Young-Whan, Baek, Nam Seok, Lee, Sungsook, Ha, Kyoung Soo, Choi, SungKu, Lee, Won Sik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Small Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978881/
https://www.ncbi.nlm.nih.gov/pubmed/36808277
http://dx.doi.org/10.1158/1535-7163.MCT-22-0068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978881/
https://www.ncbi.nlm.nih.gov/pubmed/36808277
http://dx.doi.org/10.1158/1535-7163.MCT-22-0068

Ejemplares similares